Acrivon Therapeutics | ApexOnco - Clinical Trials news and analysis

x

“I am very impressed - it has become my go-to platform”

Chief Business Officer

US public biotech company

Click here for more information

Data insights

13 November 2024

Regeneron keeps up its co-stimulatory crusade

The company’s CD38 x CD28 MAb is among recent clinical trial entrants.

Deals

7 March 2024

Boundless enthusiasm for CHK1

Conferences Trial results

16 October 2023

Triple meeting 2023 – no monotherapy activity for Repare

Subscribe to Acrivon Therapeutics